LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have C FDA Decision: Service Corporation International (SCI)

The Phase 3 date for LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have C by Service Corporation International (SCI) is scheduled for June 5, 2029. This is the target date for the FDA to make a decision on this application.

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have C is being developed by Service Corporation International for the treatment of its target indication. It is currently in Phase 3 clinical trials.

If LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have C receives FDA approval, Service Corporation International (SCI) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 3 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for SCI on DilutionWatch at dilutionwatch.com/stock/SCI.html.

You can view the full BiotechSigns company profile for Service Corporation International (SCI) at biotechsign.com/app/company/SCI, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.